LAMBERT, J.; PAUL, C.; GOTTLIEB, A.; POULIN, Y. Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s45, 2022. DOI: 10.25251/skin.6.supp.45. Disponível em: https://jofskin.org/index.php/skin/article/view/1800. Acesso em: 3 jul. 2024.